Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 1
2003 1
2004 1
2010 1
2011 1
2012 2
2013 1
2015 1
2016 1
2017 2
2018 1
2019 1
2020 2
2021 2
2022 4
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Nørgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Battelino T, et al. Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8. Diabetes Care. 2019. PMID: 31177185 Free PMC article. Review.
New levodopa therapeutic strategies.
LeWitt PA. LeWitt PA. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S37-40. doi: 10.1016/j.parkreldis.2015.09.021. Epub 2015 Sep 8. Parkinsonism Relat Disord. 2016. PMID: 26459662 Review.
Because conventional immediate-release carbidopa-levodopa tablets yield such variable pharmacokinetic profiles (as do other marketed products attempting to extend levodopa effect), improved formulations are greatly needed by patients experiencing motor fluctuations. ...
Because conventional immediate-release carbidopa-levodopa tablets yield such variable pharmacokinetic profiles (as do other marketed …
The Development of New Diagnostic Tests for Neurologic Disorders in the Commercial Laboratory Environment.
Venkataraman I, Naides SJ. Venkataraman I, et al. Clin Lab Med. 2020 Sep;40(3):331-339. doi: 10.1016/j.cll.2020.06.001. Epub 2020 Jul 2. Clin Lab Med. 2020. PMID: 32718503 Review.
Clinically characterized specimens for validation of biomarkers for esoteric diseases may be difficult to acquire, and market size may be difficult to predict. More common diseases with heterogeneous subsets may require better clinical definition. ...Regulatory agency appr …
Clinically characterized specimens for validation of biomarkers for esoteric diseases may be difficult to acquire, and market size ma …
Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.
Grunberger G. Grunberger G. J Diabetes. 2013 Jun;5(2):110-7. doi: 10.1111/1753-0407.12034. J Diabetes. 2013. PMID: 23452312 Review.
Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of the underlying pathophysiology of type 2 diabetes has advanced, attempts have been made to address these defects specifically. ...
Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of …
Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986-2020.
Feldman WB, Bloomfield D, Beall RF, Kesselheim AS. Feldman WB, et al. Health Aff (Millwood). 2022 Jun;41(6):787-796. doi: 10.1377/hlthaff.2021.01874. Epub 2022 May 17. Health Aff (Millwood). 2022. PMID: 35579925 Free PMC article.
To better understand the strategies that brand-name inhaler manufacturers have employed to preserve their market dominance, we analyzed all patents and regulatory exclusivities granted to inhalers approved by the Food and Drug Administration between 1986 and 2020. ...More …
To better understand the strategies that brand-name inhaler manufacturers have employed to preserve their market dominance, we analyz …
Safety priorities for occupant protection in rear impacts.
Viano DC. Viano DC. Traffic Inj Prev. 2023;24(3):155-172. doi: 10.1080/15389588.2023.2171177. Epub 2023 Feb 10. Traffic Inj Prev. 2023. PMID: 36763455
Priorities, countermeasure and concepts were considered to improve occupant protection in rear impacts: 1) new rear impact test with the IIHS high-hood barrier offset to the rear at 55 mph to reduce rear-seat intrusion, 2) stepped-up campaigns for proper child seat selection and …
Priorities, countermeasure and concepts were considered to improve occupant protection in rear impacts: 1) new rear impact test with the IIH …
New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.
Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. Cowie MR, et al. Eur J Heart Fail. 2017 Jun;19(6):718-727. doi: 10.1002/ejhf.809. Epub 2017 Mar 27. Eur J Heart Fail. 2017. PMID: 28345190 Free article. Review.
Collaboration between regulators, industry, clinical trialists, cardiologists, health technology assessment bodies, payers, and patient organizations is critical to address the ongoing challenge of heart failure and to ensure the development and market access of new therap …
Collaboration between regulators, industry, clinical trialists, cardiologists, health technology assessment bodies, payers, and patient orga …
A collaboratively-derived science-policy research agenda.
Sutherland WJ, Bellingan L, Bellingham JR, Blackstock JJ, Bloomfield RM, Bravo M, Cadman VM, Cleevely DD, Clements A, Cohen AS, Cope DR, Daemmrich AA, Devecchi C, Anadon LD, Denegri S, Doubleday R, Dusic NR, Evans RJ, Feng WY, Godfray HC, Harris P, Hartley SE, Hester AJ, Holmes J, Hughes A, Hulme M, Irwin C, Jennings RC, Kass GS, Littlejohns P, Marteau TM, McKee G, Millstone EP, Nuttall WJ, Owens S, Parker MM, Pearson S, Petts J, Ploszek R, Pullin AS, Reid G, Richards KS, Robinson JG, Shaxson L, Sierra L, Smith BG, Spiegelhalter DJ, Stilgoe J, Stirling A, Tyler CP, Winickoff DE, Zimmern RL. Sutherland WJ, et al. PLoS One. 2012;7(3):e31824. doi: 10.1371/journal.pone.0031824. Epub 2012 Mar 9. PLoS One. 2012. PMID: 22427809 Free PMC article.
The Lebanese Regie state-owned tobacco monopoly: lessons to inform monopoly-focused endgame strategies.
Alaouie H, Branston JR, Bloomfield MJ. Alaouie H, et al. BMC Public Health. 2022 Aug 29;22(1):1632. doi: 10.1186/s12889-022-13531-z. BMC Public Health. 2022. PMID: 36038852 Free PMC article.
Using the Regie as a practical example allows us to effectively revisit both the potential and the pitfalls of endgame strategies aiming to introduce some form of monopoly and requires a focus on: (i) establishing appropriate governance structures for the organisation; and (ii) a …
Using the Regie as a practical example allows us to effectively revisit both the potential and the pitfalls of endgame strategies aiming to …
26 results